Drug Type Bispecific antibody |
Synonyms KA 3008, KA3008 |
Target |
Action inhibitors, antagonists |
Mechanism CD276 inhibitors(CD276 antigen inhibitors), EGFR antagonists(Epidermal growth factor receptor erbB1 antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Lung Cancer | Preclinical | China | 22 Mar 2024 |